AURA Historical PE Ratio Notes

— Aura Biosciences (ticker symbol: AURA) is a clinical-stage biotechnology company focused on developing precision immunotherapies to treat cancers with high unmet medical needs, particularly those affecting the eyes and other visually accessible tissues. AURA’s lead product candidate, belzupacap sarotalocan, is in development for the treatment of choroidal melanoma, a rare & aggressive eye cancer. Because Aura Biosciences is still in the clinical-stage and has yet to generate significant product revenue, its historical earnings have generally been negative, which can lead to non-meaningful or undefined price-to-earnings (PE) ratios in the data you’ll review. When researching AURA’s historical PE ratio, you’ll likely notice gaps or extremely high (or negative) values due to the lack of profitability, a common situation for companies developing new biotechnologies. The stock market typically values such firms based on pipeline progress & future growth potential rather than current earnings, so fluctuations in AURA’s share price may reflect clinical trial results, regulatory milestones, or partnership announcements rather than changes in actual earnings. Investors often look to metrics other than historical PE ratio when evaluating early-stage biotech companies like Aura Biosciences.

On this page we presented the AURA Historical PE Ratio information for Aura Biosciences' stock. The average AURA historical PE based on using the annualized quarterly earnings result at each measurement period (for the "E" in the PE calculation; and the closing price on earnings date as the "P") is NA. Meanwhile, using the trailing twelve month (TTM) quarterly earnings result as our method of calculation the "E" value at each measurement period, the average AURA historical PE based on this TTM earnings result method is NA. Note: any PE calculations involving negative earnings were discarded as not meaningful.

Let's now compare this AURA historical PE result, against the recent PE: when this page was posted on 6/5/2026, the most recent closing price for AURA had been 6.63, and the most recent quarterly earnings result, annualized, was NA. Meanwhile, the most recent TTM earnings summed to NA.

For self directed investors doing their due diligence on AURA or any other given stock, valuation analysis for AURA can greatly benefit from studying the past earnings and resulting PE calculations. This exercise can help inform an analysis as to whether the past earnings trajectory and current versus historical PE ratios justify the current stock value.

That's why we bring you HistoricalPERatio.com to make it easy for investors to investigate Aura Biosciences PE history or the past PE information for any stock in our coverage universe. And in your continued research we hope you will be sure to check out the further links included for earnings surprises history (beat/miss data) as well as next earnings dates for AURA. Thanks for visiting, and the next time you need to research AURA Historical PE Ratio or the ratio for another stock, we hope you'll think of our site, as your go-to historical PE ratio research resource of choice.